A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy (SPARE)

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Status and phase: Completed; Phase 4

Conditions: Crohn's Disease

Treatments: Drug: AZATHIOPRINE; Drug: Methotrexate; Drug: INFLIXIMAB; Drug: MERCAPTOPURINE

Study type: Interventional

Funder types: Other

Identifiers

NCT02177071

GETAID 2014-03

Details and patient eligibility

About

Phase IV

Design : Prospective, open-label, randomized three-arms study

Main Inclusion criteria Luminal Crohn's disease patients with steroid free remission for at least 6 months and a combination therapy with infliximab and anti-metabolites for at least 8 months

Primary objective To demonstrate that Infliximab scheduled maintenance with or without antimetabolites is superior to antimetabolites alone to maintain sustained steroid-free remission over 2 years, while the latter is non inferior with regards to the mean time spent in remission over the same duration

Main co-primary end points Clinical relapse rate at 2 years Mean remission duration within 2 years Study treatment Infliximab, Mercaptopurine, azathioprine, methotrexate.

Number of subjects 225 randomized patients (75 per arm)

Study duration: 3 + 2 years Enrollment: 3 years Follow-up: 2 years

Full description

3. STUDY OBJECTIVES 3.1. Primary objective To assess the effect of two withdrawal strategies over two years in patients with stable remission for more than 6 months on combination therapy with infliximab and antimetabolites, and demonstrate that continued combination of infliximab and antimetabolites or continued monotherapy with infliximab are both superior to antimetabolites alone for maintaining sustained steroid-free clinical remission, while antimetabolites alone are non-inferior with regards to the mean time spent in remission 3.2. Secondary objectives

• To identify baseline predictive factors of relapse in the three study groups.
• To assess the ability of blood CRP and fecal calprotectin to predict short term relapse in the three groups.
• To assess time spent inclinical remission in the three groups.
• To assess the rate of treatment failure in the three study groups.
• To assess the time to treatment failure in the three study groups.
• To assess progression of bowel damage in the three groups.
• To assess the safety and efficacy of infliximab retreatment in the antimetabolites group.
• To assess safety in the three study groups.
• To assess the health related quality of life in the three study groups.
• To assess direct and indirect costs in the three study groups.
• To assess evolution of blood CRP and fecal calprotectin in the three study groups.
• To assess evolution of infliximab trough levels and ATI in the two infliximab scheduled maintenance groups.
• To assess genetic association with the various clinical and biological outcomes.
• To assess the impact of 6TGN levels on the various clinical and biological outcomes in the purine treated patients 4. STUDY POPULATION 4.1. Selection of study population Patients to be included are those who have been in steroid free remission for at least 6 months and with scheduled infliximab/antimetabolites combination therapy for at least 8 months, with a scheduled infliximab treatment administrated every 8 weeks for the last 4 months.

4.2. Source of recruitment Patients are recruited from participating GETAID IBD-centers in France, Belgium and SOIBD IBD-centers in Sweden, and selected centres in UK, Germany, Netherland and Australia 4.3. Inclusion criteria

To be eligible all of the following criteria must be met:

• Diagnosis of Crohn's disease.
• Male or female, age > 18 years.
• Currently treated with a combination therapy with infliximab and anti-metabolites for luminal Crohn's disease.
• Combined therapy with scheduled infliximab and anti-metabolites for at least 8 months.
• Scheduled administration of infliximab 5 mg/Kg every 8 weeks over the last 4 months.
• Antimetabolites administered at a stable dosage for the last 3 months: at least 1 mg/Kg or 2 mg/Kg for mercaptopurine and azathioprine, respectively, or the highest tolerated dosage if intolerance to standard dose;(lower dose than standard dose is also allowed if 6 TGN > 235 pmol) ; at least 15 mg/week subcutaneously for methotrexate.
• Patients in steroid free clinical remission for at least 6 months according to retrospective assessment of the patients' files.
• CDAI < 150 at baseline.
• A contraceptive during the whole study
• Patients able to understand the information provided to them and to give written informed consent for the study

4.4. Exclusion criteria

• Patients who have presented a severe acute or delayed reaction to infliximab.
• Perianal fistulae as the main indication for infliximab treatment
• Active perianal/abdominal fistulae at time of inclusion, defined by active drainage
• Patients with ostomy or ileoanal pouch
• Pregnancy or planned pregnancy during the study
• Inability to follow study procedures as judged by the investigator
• Non-compliant subjects.
• Participation in another therapeutic study

Enrollment: 211 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Crohn's disease.
• Male or female, age > 18 years.
• Currently treated with a combination therapy with infliximab and anti-metabolites for luminal Crohn's disease.
• Combined therapy with scheduled infliximab and anti-metabolites for at least 8 months.
• Scheduled administration of infliximab 5 mg/Kg every 8 weeks over the last 4 months.
• Antimetabolites administered at a stable dosage for the last 3 months: at least 1 mg/Kg or 2 mg/Kg for mercaptopurine and azathioprine, respectively, or the highest tolerated dosage if intolerance to standard dose; at least 15 mg/week subcutaneously for methotrexate.
• Patients in steroid free clinical remission for at least 6 months according to retrospective assessment of the patients' files.
• CDAI < 150 at baseline.
• A contraceptive during the whole study for childbearing potential female patients.
• Patients able to understand the information provided to them and to give written informed consent for the study

Exclusion criteria

• Patients who have presented a severe acute or delayed reaction to infliximab.
• Perianal fistulae as the main indication for infliximab treatment
• Active perianal/abdominal fistulae at time of inclusion, defined by active drainage
• Patients with ostomy or ileoanal pouch
• Pregnancy or planned pregnancy during the study
• Inability to follow study procedures as judged by the investigator
• Non-compliant subjects.
• Participation in another therapeutic study
• Steroid use ≤6 months prior to screening
• Currently receiving steroids, immunosuppressive agents (other than purine, methotrexate), biologic treatment (other than infliximab) or thalidomide

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

211 participants in 3 patient groups

INFLIXIMAB AND ANTI METABOLITE

No Intervention group

Description:

continuing scheduled infliximab treatment and anti-metabolite

STOP INFLIXIMAB CONTINUING ANTI METABOLITE

Other group

Description:

discontinuing infliximab and continuing the anti-metabolite

Treatment:

Drug: INFLIXIMAB

CONTINUING INFLIXIMAB AND discontinuing anti-metabolites

Other group

Description:

CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE

Treatment:

Drug: MERCAPTOPURINE

Drug: AZATHIOPRINE

Drug: Methotrexate